Overview

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of Pristiq® in treatment of the symptoms of Generalized Social Anxiety Disorder (SAD).
Phase:
Phase 4
Details
Lead Sponsor:
The Medical Research Network
Collaborator:
Pfizer
Treatments:
Desvenlafaxine Succinate